Abstract
Dear Editor, Pathology stewardship dictates that serial antinuclear antibody (ANA) monitoring has little clinical value and leads to a waste of resources. Furthermore, ANAs generally retain stability over time and negate the need for repeated testing. However, one situation where serial ANA monitoring may be warranted is in drug-induced lupus erythematosus (DILE). As a heterogeneous condition caused by an increasing variety of biologic agents, DILE remains difficult to recognise yet often reversible via the withdrawal of the offending agent.
In DILE patients, it is not unreasonable to check the patient’s baseline serum ANA before commencement of an agent that is known to induce DILE, such as anti-TNF inhibitors...
In DILE patients, it is not unreasonable to check the patient’s baseline serum ANA before commencement of an agent that is known to induce DILE, such as anti-TNF inhibitors...
Original language | English |
---|---|
Pages (from-to) | 2022-2023 |
Number of pages | 2 |
Journal | Rheumatology |
Volume | 60 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2021 |
Keywords
- antinuclear antibody
- lupus erythematosus
- drug-induced